NHC and NDRC Launch Expansion and Quality Enhancement Plan for Rehabilitation and Nursing Care – 0.48 Beds per 1,000 Population Targeted by 2030
Policy / Regulatory

NHC and NDRC Launch Expansion and Quality Enhancement Plan for Rehabilitation and Nursing Care – 0.48 Beds per 1,000 Population Targeted by 2030

China's National Health Commission (NHC) and the National Development and Reform Commission (NDRC) jointly issued the Notice on the Implementation Plan for the Expansion and Quality Enhancement Project of Medical…

BioMarin's Vosoritide Wins NMPA Approval in China – First CNP-Analog Therapy for Pediatric Achondroplasia Enters the World's Largest Rare Bone Disease Market
CompanyDrug

BioMarin’s Vosoritide Wins NMPA Approval in China – First CNP-Analog Therapy for Pediatric Achondroplasia Enters the World’s Largest Rare Bone Disease Market

FDA Approves AbbVie's Tavapadon as Juvmo for Parkinson's Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfoli
CompanyDrug

FDA Approves AbbVie’s Tavapadon as Juvmo for Parkinson’s Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfolio

Jenscare's JensClip Wins NMPA Registration Approval – Self‑Locking Transcatheter Mitral Valve Repair Clip Enters the Chinese Market
CompanyMedical Device

Jenscare’s JensClip Wins NMPA Registration Approval – Self‑Locking Transcatheter Mitral Valve Repair Clip Enters the Chinese Market

Merck's Subcutaneous Pembrolizumab Approved by China's NMPA Across 19 Solid Tumor Indications – First and Only Subcutaneous PD‑1 Inhibitor in China
CompanyDrug

Merck’s Subcutaneous Pembrolizumab Approved by China’s NMPA Across 19 Solid Tumor Indications – First and Only Subcutaneous PD‑1 Inhibitor in China

FDA Approves Priovant's LISRAYA (Brepocitinib) for Adult Dermatomyositis – First Oral Targeted JAK1/TYK2 Therapy in the Indication
CompanyDrug

FDA Approves Priovant’s LISRAYA (Brepocitinib) for Adult Dermatomyositis – First Oral Targeted JAK1/TYK2 Therapy in the Indication

Northland Biotech's Sedominji Completes First National Shipment – World's First Approved HGF Naked Plasmid Gene Therapy Reaches CLI Patients in Nine Provinces
CompanyDrug

Northland Biotech’s Sedominji Completes First National Shipment – World’s First Approved HGF Naked Plasmid Gene Therapy Reaches CLI Patients in Nine Provinces

GeneScience's GenSci161 Wins NMPA Acceptance for Recurrent Pericarditis Clinical Trial – Novel Fully Human IL‑1α/IL‑1β Bispecific Antibody
CompanyDrug

GeneScience’s GenSci161 Wins NMPA Acceptance for Recurrent Pericarditis Clinical Trial – Novel Fully Human IL‑1α/IL‑1β Bispecific Antibody

Youcare Pharmaceutical's YKYY036 Wins Dual Clinical Clearances from NMPA and FDA – GalNAc‑Conjugated siRNA Targeting INHBE Advances Global Obesity Program
CompanyDrug

Youcare Pharmaceutical’s YKYY036 Wins Dual Clinical Clearances from NMPA and FDA – GalNAc‑Conjugated siRNA Targeting INHBE Advances Global Obesity Program

Regeneron Reports Positive 84‑Week Phase 3 OPTIMA Results for Pasatru in FOP – No New Heterotopic Ossification Lesions After Week 56 vs Nine for Placebo
CompanyDrug

Regeneron Reports Positive 84‑Week Phase 3 OPTIMA Results for Pasatru in FOP – No New Heterotopic Ossification Lesions After Week 56 vs Nine for Placebo

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

Hangzhou Defand Therapeutics Co., Ltd. (Defand) announced that it has entered into a research collaboration and licensing agreement with Roche (SWX: ROP; OTCMKTS: RHHBY) to jointly discover and develop novel molecular glue degraders (MGDs) targeting multiple therapeutic targets in oncology…

Jiangsu Nhwa Signs Exclusive Global Licensing Deal with Somnivera – Clinical‑Stage Sleep‑Disorder Asset Backed by Up to US$517.5 Million in Potential Value

Jiangsu Nhwa Signs Exclusive Global Licensing Deal with Somnivera – Clinical‑Stage Sleep‑Disorder Asset Backed by Up to US$517.5 Million in Potential Value

Yatai Pharma Subsidiary Shengyao Guangyan Signs LOI to Acquire BODIPY‑Type Photosensitizer for Acne – Class 1.1 Photodynamic Asset with Up to RMB 65 Million in Milestones Plus Royalties
CompanyDeals

Yatai Pharma Subsidiary Shengyao Guangyan Signs LOI to Acquire BODIPY‑Type Photosensitizer for Acne – Class 1.1 Photodynamic Asset with Up to RMB 65 Million in Milestones Plus Royalties

AbbVie Announces Phase 3 AFFIRM Data for SKYRIZI Subcutaneous Induction in Crohn's Disease – 35.8% Achieved Endoscopic Remission
CompanyDrug

AbbVie Announces Phase 3 AFFIRM Data for SKYRIZI Subcutaneous Induction in Crohn’s Disease – 35.8% Achieved Endoscopic Remission

Shenzhen Kangtai Initiates Phase I Trial of Self‑Developed DTaP Combination Vaccine – First‑in‑China Candidate for Adults, Adolescents and Children
CompanyDrug

Shenzhen Kangtai Initiates Phase I Trial of Self‑Developed DTaP Combination Vaccine – First‑in‑China Candidate for Adults, Adolescents and Children

J&J Announces Phase 3 Data Showing TREMFYA Delivers Combined Fistula Remission in Crohn's Disease with Perianal Fistula – Only IL‑23 Inhibitor with Dedicated Trial Success
CompanyDrug

J&J Announces Phase 3 Data Showing TREMFYA Delivers Combined Fistula Remission in Crohn’s Disease with Perianal Fistula – Only IL‑23 Inhibitor with Dedicated Trial Success

Hengrui Wins NMPA Clinical Trial Approval for SHR‑3201 – First‑in‑Class Investigational Therapy Targeting Alzheimer's Disease
CompanyDrug

Hengrui Wins NMPA Clinical Trial Approval for SHR‑3201 – First‑in‑Class Investigational Therapy Targeting Alzheimer’s Disease

Where biopharma's biggest deals take shape!

Your front-row seat to the deals reshaping the pharmaceutical landscape — mergers and acquisitions, licensing agreements, venture investments, and strategic partnerships. We track every major transaction, from blockbuster M&As to early-stage funding rounds, breaking down what each deal means for the companies, the pipeline, and the market.
M&A and Licensing
Wuhan Hiteck Licenses HT006.2.2 rhNGF Eye Drops to Visara for Ex‑Greater China – Up to USD 111 Million Deal Advances Next‑Generation Neurotrophic Keratitis Therapy
CompanyDeals

Wuhan Hiteck Licenses HT006.2.2 rhNGF Eye Drops to Visara for Ex‑Greater China – Up to USD 111 Million Deal Advances Next‑Generation Neurotrophic Keratitis Therapy

Wuhan Hiteck Biological Pharma Co., Ltd. (SHE: 300683) announced that it has signed an exclusive collaboration and licensing agreement with Visara, Inc., a U.S. clinical‑stage biopharmaceutical company focused on innovative…

Roche Inks Exclusive Worldwide License With Rona Therapeutics for ALK7‑Targeting RNAi Candidate – Up to USD 1.16 Billion Deal Advances Genetically Validated Obesity Target via Extrahepatic Delivery
CompanyDeals

Roche Inks Exclusive Worldwide License With Rona Therapeutics for ALK7‑Targeting RNAi Candidate – Up to USD 1.16 Billion Deal Advances Genetically Validated Obesity Target via Extrahepatic Delivery

Allygen Biologics Closes Over RMB 300 Million Series A Led by Sherpa Healthcare Partners – Funding to Propel STAR‑BiADC Candidate ALG01 into Phase 1
CompanyDeals

Allygen Biologics Closes Over RMB 300 Million Series A Led by Sherpa Healthcare Partners – Funding to Propel STAR‑BiADC Candidate ALG01 into Phase 1

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech's CNS and Brain‑Penetrant Drug Pipeline
CompanyDeals

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech’s CNS and Brain‑Penetrant Drug Pipeline

Chai Discovery Announces Collaboration with GSK – AI Protein Folding and Design Platform to Power Drug Discovery Across GSK's Pipeline
CompanyDeals

Chai Discovery Announces Collaboration with GSK – AI Protein Folding and Design Platform to Power Drug Discovery Across GSK’s Pipeline

- Advertisement -
Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances "Closed‑Loop Nerve Bundle Modulation" Platform
CompanyDeals

Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances “Closed‑Loop Nerve Bundle Modulation” Platform

Tangzhi Pharma Secures Nearly RMB 100 Million Exclusive Financing from Fengnian Capital – Glyco Raw‑Material Platform Targets ADC and Nucleic‑Acid Drug Boom
CompanyDeals

Tangzhi Pharma Secures Nearly RMB 100 Million Exclusive Financing from Fengnian Capital – Glyco Raw‑Material Platform Targets ADC and Nucleic‑Acid Drug Boom

Medicovestor Completes Seed Funding Round to Advance Next-Generation Antibody and ADC Pipeline – MC004 Naked Antibody Targets FDA IND Filing by Early 2027
CompanyDeals

Medicovestor Completes Seed Funding Round to Advance Next-Generation Antibody and ADC Pipeline – MC004 Naked Antibody Targets FDA IND Filing by Early 2027

Medinno Pharmaceutical Closes Over RMB 200 Million Series A Led by Sunshine Ronghui Capital – MDI‑1228, World's First Topical Pan‑JAK/Pan‑Trk Inhibitor, Advances Global Clinical Development
CompanyDeals

Medinno Pharmaceutical Closes Over RMB 200 Million Series A Led by Sunshine Ronghui Capital – MDI‑1228, World’s First Topical Pan‑JAK/Pan‑Trk Inhibitor, Advances Global Clinical Development

MIIT and Nine Departments Issue China's "15th Five‑Year Plan for Pharmaceutical Industry Development" – Innovative Drug Sector Targeted to Grow Over 20 % Annually Through 2030
Policy / Regulatory

MIIT and Nine Departments Issue China’s “15th Five‑Year Plan for Pharmaceutical Industry Development” – Innovative Drug Sector Targeted to Grow Over 20 % Annually Through 2030

The Ministry of Industry and Information Technology (MIIT), together with nine other departments, formulated and issued the "15th Five‑Year Plan for Pharmaceutical Industry Development" (the "Plan"), setting quantitative industry targets…

Five Innovative Therapies Enter the Rare Disease R&D Pilot Initiative – Spanning Blau Syndrome, Angelman Syndrome, ALS and Charcot‑Marie‑Tooth Disease
Policy / Regulatory

Five Innovative Therapies Enter the Rare Disease R&D Pilot Initiative – Spanning Blau Syndrome, Angelman Syndrome, ALS and Charcot‑Marie‑Tooth Disease

China's CDE Launches "Pioneer Plan" Pilot to Advance New Approach Methodologies (NAMs) in Non‑Clinical Drug Evaluation – Aiming to Reduce, Refine, and Replace Animal Testing
Policy / Regulatory

China’s CDE Launches “Pioneer Plan” Pilot to Advance New Approach Methodologies (NAMs) in Non‑Clinical Drug Evaluation – Aiming to Reduce, Refine, and Replace Animal Testing

China's NMPA Unveils Draft Regulations on Radiopharmaceuticals – Public Consultation Open Through October 20 With Priority Review for Urgent‑Demand Products
Policy / Regulatory

China’s NMPA Unveils Draft Regulations on Radiopharmaceuticals – Public Consultation Open Through October 20 With Priority Review for Urgent‑Demand Products

More News

Suzhou Zelgen Submits NDA to NMPA for Gecacitinib's Third Indication – Novel JAK inhibitor Targeting Active Ankylosing Spondylitis
CompanyDrug

Suzhou Zelgen Submits NDA to NMPA for Gecacitinib’s Third Indication – Novel JAK inhibitor Targeting Active Ankylosing Spondylitis

Johnson & Johnson Posts Q3 2026 Revenue of USD 25.4 Billion, Raises Full‑Year Guidance – Innovative Medicine Drives 6.0% Operational Growth
Company

Johnson & Johnson Posts Q3 2026 Revenue of USD 25.4 Billion, Raises Full‑Year Guidance – Innovative Medicine Drives 6.0% Operational Growth

InnoCare's Mesutoclax Wins CDE Approval for Registrational Phase III Trial With Orelabrutinib in Relapsed/Refractory MZL – Fifth Registrational Study for China's First BTD‑Designated BCL2 Inhibitor
CompanyDrug

InnoCare’s Mesutoclax Wins CDE Approval for Registrational Phase III Trial With Orelabrutinib in Relapsed/Refractory MZL – Fifth Registrational Study for China’s First BTD‑Designated BCL2 Inhibitor

Laekna's LAE102 Delivers Promising Weight Loss With Lean Mass Gains in Completed 24‑Week Low‑Dose Monotherapy Cohorts – Selective ActRIIA Antibody Well Tolerated, High‑Dose Cohort Fully Enrolled
CompanyDrug

Laekna’s LAE102 Delivers Promising Weight Loss With Lean Mass Gains in Completed 24‑Week Low‑Dose Monotherapy Cohorts – Selective ActRIIA Antibody Well Tolerated, High‑Dose Cohort Fully Enrolled

CARsgen Doses First Patient in Registrational Phase I Trial of CT0596 – Allogeneic BCMA CAR‑T Built on THANK‑u Plus® Platform Advances Toward Relapsed/Refractory Multiple Myeloma
CompanyDrug

CARsgen Doses First Patient in Registrational Phase I Trial of CT0596 – Allogeneic BCMA CAR‑T Built on THANK‑u Plus® Platform Advances Toward Relapsed/Refractory Multiple Myeloma

Sansure Biotech's Quadruplex Respiratory Pathogen PCR Kit Wins NMPA Registration – Second Lyophilized Four‑in‑One Test Extends AI‑Driven Respiratory Panel Portfolio to Eight Pathogens
CompanyMedical Device

Sansure Biotech’s Quadruplex Respiratory Pathogen PCR Kit Wins NMPA Registration – Second Lyophilized Four‑in‑One Test Extends AI‑Driven Respiratory Panel Portfolio to Eight Pathogens

Guangdong True Health Medical's Gene‑Edited Pig Liver Perfusion Support Sets 144‑Hour Global Record – World's First Prolonged Xenotransplantation Efficacy Validation in Preclinical Acute Liver Failure Model
Company

Guangdong True Health Medical’s Gene‑Edited Pig Liver Perfusion Support Sets 144‑Hour Global Record – World’s First Prolonged Xenotransplantation Efficacy Validation in Preclinical Acute Liver Failure Model

Sinocelltech's SCT810 Injection Wins NMPA Clearance for Phase I/II Study – Anti‑TFPI Antibody Offers Factor‑Independent Prophylaxis for Hemophilia A and B With or Without Inhibitors
CompanyDrug

Sinocelltech’s SCT810 Injection Wins NMPA Clearance for Phase I/II Study – Anti‑TFPI Antibody Offers Factor‑Independent Prophylaxis for Hemophilia A and B With or Without Inhibitors

Show More